Abstract 78P
Background
Circadian rhythms (CRs) are 24-hour cycles involved in fundamental aspects of the organism's physiology, such as cell cycle control, metabolism, or immune responses. While the notion of CR abrogation and cancer is well-known, the specific mechanisms that control rhythmic responses in the tumor microenvironment (TME) are not fully understood. Here, we aim to dissect these programs in NSCLC, with the goal of harnessing circadian biology in a therapeutic setting.
Methods
Using a preclinical model of NSCLC (K-rasMUTTp53-/- cell line, KP) orthotopically transferred to C57BL/6 mice, we evaluated daily fluctuations of oncogenic programs, profiled the immune microenvironment, and assessed therapeutic response to anti-PD1 across the day. We also analyzed mice lacking circadian functions in myeloid cells, the main immune infiltrate of KP tumors.
Results
KP tumoral burden showed daily regulation, being higher during the resting phase. Interestingly, transcriptome analysis of FACS-sorted cancer cells over 24h revealed a pro-tumoral program dominated by glycolysis, hypoxia, and mTORC1 increased signaling, which is exacerbated at noon. Strikingly, KP tumors lacking BMAL1 showed increased CD8+ T cell infiltration and reduced tumoral load, suggesting tumor glycolysis controlled by BMAL1, and that its loss promotes anti-tumor immunity. As dendritic cells and CD8+ T cells exert a circadian anti-tumor role in melanoma, we verified whether T cell immunity can be therapeutically exploited in our model. Anti-PD1 efficacy was improved during the active phase, as revealed by a rise in tumor-antigen specific CD8+ T cells, enhanced tumoral clearance and better clinical score. Furthermore, using mice lacking CRs in myeloid cells, we observed different tumor outcomes. Bmal1 loss in neutrophils promoted bigger tumors and more myeloid cell infiltration in KP tumors. Conversely, Bmal1 deletion in CD11c-expressing cells led to lower tumoral burden, being these tumors enriched in cytotoxic CD8+ T cells.
Conclusions
Together, our results suggest time-dependent pro-tumoral mechanisms controlled by BMAL1 in the TME of NSCLC. Dissecting circadian programs controlled by BMAL1 will be key for the proper design of therapeutic interventions in lung cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Ramón y Cajal Programme 2021; CNIO Excellence Programme; ERC StG 2022.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract